NASDAQ NMS - GLOBAL MARKET · REGN

-1.08% · -$6.74

Regeneron Pharmaceuticals Inc

Biotechnology

$614.78

+ Add to watchlist

Veridion Score

BETAHIGH CONF · 5/6 factors

As of May 31, 8:57 PM EDT · REGN

Methodology

60/100

BUY BIAS

Composite intelligence score across six weighted factors. Higher score = stronger composite signal.

Score history: Coverage building

Institutional Flow · 90D

Corporate Insiders

SEC Form 4

43/ 100

-369K net shares (90d) · 0B / 21S

US Congress

Senate eFD + House STOCK Act

—/ 100

no data

Wall Street Analysts

Sell-side consensus

77/ 100

11 SB · 19 B · 8 H

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Insider · Congress · Wall Street flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 5/6 factors with data · Computed May 31, 8:57 PM EDT · Refreshes hourly

Share on X →

Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…

REFRESHES DAILY

AI Analysis

BETA

Why is REGN moving today?

Analyzing news articles + insider activity + analyst signals…

About Regeneron Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS

Founded

—

Listed

1991

Employees

15K

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Company website →

Open

$620.11

Previous close

$621.52

Day high

$624.47

Day low

$609.77

Market cap

$64.45B

IPO

1991-04-02

Country

Currency

USD

Data ledger

Quote and day range

As of May 29, 4:00 PM EDT

Source: Market data

Veridion Score

As of May 31, 8:57 PM EDT

Source: Veridion methodology

Chart and risk context

Daily bars with no missing-bar fill

Source: Market data

News and filings

Refresh intervals shown inside each panel

Source: Market news and federal filings

Financials

Loading quarterly statements…

Insider activity · 6M

Loading Form 4 filings…

Congress · 90D

Loading PTR filings…

Federal contracts

REGN contract awards, year to date.

Public federal awards linked to this ticker.

—

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for REGN in this window.

Lobbying spend

REGN lobbying filings, year to date.

Registered lobbying filings matched to Regeneron Pharmaceuticals Inc.

$1.5M

Refresh interval: 12hSource: LDA disclosure filings

Health IssuesHealth Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue CodeTaxation/Internal Revenue Code Health Issues Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)

Filing

$640.0K

REGENERON PHARMACEUTICALS INC

REGENERON PHARMACEUTICALS, INC

Apr 20, 2026

Filing

$610.0K

REGENERON PHARMACEUTICALS INC

REGENERON PHARMACEUTICALS, INC

Jan 20, 2026

Filing

$90.0K